Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antifibrotic Agents for the Management of CKD: A Review

  • Ruiz-Ortega, Marta
  • Lamas Peláez, Santiago
  • Ortiz, Alberto
Kidney fibrosis is a hallmark of chronic kidney disease (CKD) and a potential therapeutic target. However, there are conceptual and practical challenges to directly targeting kidney fibrosis. Whether fibrosis is mainly a cause or a consequence of CKD progression has been disputed. It is unclear whether specifically targeting fibrosis is feasible in clinical practice because most drugs that decrease fibrosis in preclinical models target additional and often multiple pathogenic pathways (eg, renin-angiotensin-aldosterone system blockade). Moreover, tools to assess whole-kidney fibrosis in routine clinical practice are lacking. Pirfenidone, a drug used for idiopathic pulmonary fibrosis, is undergoing a phase 2 trial for kidney fibrosis. Other drugs in use or being tested for idiopathic pulmonary fibrosis (eg, nintedanib, PRM-151, epigallocatechin gallate) are also potential candidates to treat kidney fibrosis. Novel therapeutic approaches may include antagomirs (eg, lademirsen) or drugs targeting interleukin 11 or NKD2 (WNT signaling pathway inhibitor). Reversing the dysfunctional tubular cell metabolism that leads to kidney fibrosis offers additional therapeutic opportunities. However, any future drug targeting fibrosis of the kidneys should demonstrate added benefit to a standard of care that combines renin-angiotensin system with mineralocorticoid receptor (eg, finerenone) blockade or with sodium/glucose cotransporter 2 inhibitors., This work was supported by grants from Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119, PI20/00140, DTS20/00083, PI18/01366, PI19/00588, PI19/00815, DTS18/00032, Red de Investigacion Renal REDINREN: RD16/0009, RICORS2040 RD21/0005/0001) Comunidad Autonoma de Madrid FEDER-a way to build Europe (B2017/ BMD-3751 NOVELREN-CM to MR-O and SL); Convocatoria Dinamizacion Europa Investigacion 2019 ” MINECO (EIN2019-103294 to M.R-O B2017/BMD-3686 CIFRA2-CM to AO); Innovation programme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMPROVE-PD ID: 812699) to MR-O; and ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, Sociedad Espanola de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina and Ministerio de Ciencia e Innovación: PID2019-104233RB-I00/AEI/10.13039/501100011033 to SL
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice

  • Opazo-Ríos, Lucas
  • Tejera-Muñoz, Antonio
  • Soto Catalan, Manuel
  • Marchant, Vanessa
  • Mas Fontao, Sebastián
  • Lavoz, Carolina
  • Moreno, Juan Antonio
  • Fierro Fernandez, Marta
  • Ramos, Ricardo
  • Suarez-Alvarez, Beatriz
  • López-Larrea, Carlos
  • Ruiz-Ortega, Marta
  • Egido, Jesús
  • Rodrigues-Díez, Raúl R.
Diabetic nephropathy (DN) is the main leading cause of chronic kidney disease worldwide. Although remarkable therapeutic advances have been made during the last few years, there still exists a high residual risk of disease progression to end-stage renal failure. To further understand the pathogenesis of tissue injury in this disease, by means of the Next-Generation Sequencing, we have studied the microRNA (miRNA) differential expression pattern in kidneys of Black and Tan Brachyury (BTBR) ob/ob (leptin deficiency mutation) mouse. This experimental model of type 2 diabetes and obesity recapitulates the key histopathological features described in advanced human DN and therefore can provide potential useful translational information. The miRNA-seq analysis, performed in the renal cortex of 22-week-old BTBR ob/ob mice, pointed out a set of 99 miRNAs significantly increased compared to non-diabetic, non-obese control mice of the same age, whereas no miRNAs were significantly decreased. Among them, miR-802, miR-34a, miR-132, miR-101a, and mir-379 were the most upregulated ones in diabetic kidneys. The in silico prediction of potential targets for the 99 miRNAs highlighted inflammatory and immune processes, as the most relevant pathways, emphasizing the importance of inflammation in the pathogenesis of kidney damage associated to diabetes. Other identified top canonical pathways were adipogenesis (related with ectopic fatty accumulation), necroptosis (an inflammatory and regulated form of cell death), and epithelial-to-mesenchymal transition, the latter supporting the importance of tubular cell phenotype changes in the pathogenesis of DN. These findings could facilitate a better understanding of this complex disease and potentially open new avenues for the design of novel therapeutic approaches to DN., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/ 00119, PI17/01495, PI17/00130, PI20/00140, PI19/00184, PI20/00639, PI20/00487, PI20/00375, DTS20/00083, and DTS19/00093), Red de Investigación Renal REDINREN: RD16/0009 to MR-O (RD16/0009/0003) and to CL-L (RD16/0009/0020), Sociedad Española de Nefrología, “NOVELREN-CM: Enfermedad renal crónica: nuevas Estrategias para la prevención, Diagnóstico y tratamiento” (B2017/BMD-3751 to MR-O), “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN 2019-103294 to MR-O), Innovation programme under the Marie SkłodowskaCurie grant of the European Union’s Horizon 2020 (IMProve-PD ID: 812699 to MR-O), Spanish Biomedical Research Centre in Cardiovascular Diseases (CIBERCV), Spanish Ministry of Science and Innovation (RYC-2017- 22369), Consejería de Salud y Familias-FEDER, Junta de Andalucía (PIGE-0052-2020 to JM), and Gobierno de Chile (S-2020-05 VIDCA-UACh to CL). RICORS program to RICORS2040 (KIDNEY DISEASE) RD21/0005/0002 to MRO; RD21/0005/0017 to CL-L.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

STING inhibition alleviates experimental peritoneal damage: potential therapeutic relevance for peritoneal dialysis

  • Marchant, Vanessa
  • García-Giménez, Jorge
  • González-Mateo, Guadalupe T
  • Sandoval, Pilar
  • Tejedor-Santamaria, Lucía
  • Rayego-Mateos, Sandra
  • Ramos, Ricardo
  • Jiménez-Heffernan, José A
  • Ortiz, Alberto
  • Raby, Anne-Catherine
  • López-Cabrera, Manuel
  • Ramos, Adrián M
  • Ruiz-Ortega, Marta
Peritoneal dialysis (PD) is a widely used kidney replacement therapy for patients with end-stage kidney disease. Nevertheless, long-term exposure to PD fluid can damage the peritoneal membrane, leading to ultrafiltration failure and, ultimately, discontinuation of PD. Investigation of the molecular mechanisms underlying this damage is essential for identifying new therapeutic targets to mitigate peritoneal deterioration in PD patients. To this end, we employed RNA sequencing in a preclinical model of peritoneal injury, induced by prolonged chlorhexidine (CHX) exposure, which revealed cytosolic DNA-sensing signaling as a novel pathway. Next, we demonstrated that key players in this pathway, such as the stimulator of interferon genes (STING) and its downstream signaling effectors (interferon regulatory factor 3, interferon-stimulated genes, and nuclear factor-κB signaling), were upregulated in experimental peritoneal damage. Moreover, increased STING expression was observed in human peritoneal biopsies from patients with PD. Subsequent studies in STING-deficient mice showed reduced proinflammatory gene expression and immune cell infiltration, together with inhibited nuclear factor-κB pathway activation at both early (10 days) and late (30 days) stages of CHX-induced peritoneal injury. STING deficiency also reduced peritoneal membrane thickening, fibrosis, and mesothelial-to-mesenchymal transition (MMT)-related changes in advanced CHX-induced damage. Furthermore, pharmacological inhibition of STING with C-176 attenuated CHX-induced peritoneal inflammation. Macrophages were identified as one of the STING-expressing cell types in the injured peritoneum. Hence, in vitro STING blockade in activated macrophages inhibited MMT in cultured mesothelial cells, suggesting that STING activation in this population may drive peritoneal fibrosis. Additionally, STING deficiency reduced peritoneal inflammation in S. epidermidis-induced peritonitis and decreased adhesion scores in a postsurgical intra-abdominal adhesion model. These findings identify STING as a pivotal mediator of peritoneal injury and support its potential as a novel therapeutic target to prevent PD-associated ultrafiltration failure. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., This study was funded by the Instituto de SaludCarlos III (ISCIII) through the projects PI20/00140, PI21/01453, PI23/00394, and RICORS2040-RD21/ 0005/0002, RD21/0005/0018, RD24/0004/0021, and RD24/0004/0001 and cofunded by the European Union- NextGenerationEU,Mecanismo para la recuperacion y la resiliencia (MRR). The grant IMPROVE-PD from the European Union’s Horizon 2020 research and innovation program, under the Marie Skłodowska-Curie grant 812699, to ML-C, VM and MR-O. INNOREN ‘P2022/ BMD-7221: Nuevas estrategias diagnosticas y terapéuticas en enfermedad renal cronica’ to VM and MR-O. Miguel Servet CP23/00025 to SR-M.